Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Boaz Nachmias*, Svetlana Krichevsky, Dvora Filon, Ehud Even-Or, Moshe E. Gatt, Revital Saban, Batia Avni, Sigal Grisariu, Shlomzion Aumann, Vladimir Vainstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

Original languageAmerican English
Pages (from-to)642-649
Number of pages8
JournalActa Haematologica
Issue number6
StatePublished - 1 Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.


  • Acute myeloid leukemia
  • Minimal residual disease
  • RUNX1 mutation


Dive into the research topics of 'Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this